GENPREX INC
GNPXNASDAQTrading Snapshot
- Day Range
- $4.37 – $4.49
- 52-Week Range
- $4.00 – $1,210.00
- Volume
- $1.78B
- Avg Volume
- $2.05B
- Shares Outstanding
- 504,934
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $247,418
- Last Q Revenue
- $58,045
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-52.93
- Dividend Yield
- 0.00%
Why Investors Own GNPX
- ✓High-growth profile — revenue up +50.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GENPREX INC
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)
Genprex Shares Rise After Collaboration With Roche Diagnostics
Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC).
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus Pharmaceuticals
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2 H-scores and low